Related Experiment Videos
Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study
B Chevallier1, S Leyvraz, J P Olivier
1Centre Régional de Lutte contre le Cancer, CRLCC, Rouen, France.
Cancer Investigation
|January 1, 1993
Summary
This study found that combining Epirubicin and Ifosfamide chemotherapy is effective for advanced soft tissue sarcoma, showing a 48% partial response rate with manageable side effects. Further trials are needed to compare it against Epirubicin alone.
Area of Science:
- Medical Oncology
- Pharmacology
- Clinical Trials
Background:
- Advanced soft tissue sarcoma (STS) presents a therapeutic challenge.
- Evaluating novel chemotherapy regimens is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the efficacy and toxicity of a combination regimen of Epirubicin and Ifosfamide in patients with advanced STS.
- To determine response rates, time to progression, and safety profile of this combined chemotherapy.
Main Methods:
- Phase II clinical trial involving 30 patients with previously untreated advanced STS.
- Administered Epirubicin (100 mg/m2) with Ifosfamide (2.5 g/m2) every 3 weeks, with dose adjustments for Epirubicin.
- Assessed efficacy using partial response rates and time to progression; evaluated toxicity via WHO criteria.
Main Results:
- Achieved a 48% partial response rate in 27 evaluable patients.
- Median time to progression was 27 weeks.
- Common toxicities included nausea, vomiting, stomatitis, and alopecia; 3 patients discontinued treatment due to cardiac dysfunction.
Conclusions:
- The combination of Epirubicin and Ifosfamide demonstrates efficacy in advanced soft tissue sarcoma with an acceptable toxicity profile.
- This regimen offers a potential treatment option for advanced STS.
- Further studies are required to ascertain if this combination is superior to Epirubicin monotherapy.